semaglutide not for human use versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial Weight loss with GLP-1 medicines

And the questions around What is tapering and is it right for me? start to take hold

Explosive Growth in GLP-1Adjacent Supplements: The broader GLP-1 support supplement market is expanding rapidly alongside prescription GLP-1 drug adoption, with projections showing sustained double-digit growth driven by consumer interest in metabolic health and weight management solutions

NHS access to weight management services remains limited in practice

La semaglutida est indicada para el control de peso crnico en adultos con un IMC de 27 kg/m o ms que tengan al menos una comorbilidad relacionada con el peso, como diabetes tipo 2 o hipertensin, o en adultos con un IMC de al menos 30 kg/m

Additionally, limit the use of aspirin and other NSAIDs